|
|
Exact Sciences Corporation (EXAS) |
|
Price: $65.8200
$-0.17 
-0.258%
|
| Day's High:
| $66.71
| Week Perf:
| -2.18 %
|
| Day's Low: |
$ 64.02 |
30 Day Perf: |
7.23 % |
| Volume (M): |
1,026 |
52 Wk High: |
$ 100.77 |
| Volume (M$): |
$ 67,498 |
52 Wk Avg: |
$71.30 |
| Open: |
$65.47 |
52 Wk Low: |
$40.73 |
|
|
| Market Capitalization (Millions $) |
12,116 |
| Shares
Outstanding (Millions) |
184 |
| Employees |
5,361 |
| Revenues (TTM) (Millions $) |
2,408 |
| Net Income (TTM) (Millions $) |
-282 |
| Cash Flow (TTM) (Millions $) |
359 |
| Capital Exp. (TTM) (Millions $) |
162 |
Exact Sciences Corporation
Exact Sciences Corporation is a medical technology company headquartered in Madison, Wisconsin, that is focused on developing and commercializing diagnostic tests for the early detection and prevention of cancer. Founded in 1995, the company has risen to prominence as a leader in the field of molecular diagnostics, a branch of medicine that uses DNA and RNA analysis to identify and diagnose diseases.
The company's flagship product is Cologuard, a non-invasive, at-home fecal immunochemical test (FIT) for colorectal cancer screening. Cologuard uses advanced DNA and protein analysis to detect signs of colorectal cancer and precancerous growths, offering patients a comfortable and convenient alternative to traditional colonoscopies. Since its launch in 2014, Cologuard has become one of the most widely used and highly rated colorectal cancer screening tests in the United States.
In addition to Cologuard, Exact Sciences also offers a suite of other diagnostic products for cancer detection, including Oncotype DX, a genomic test for breast, colon, and prostate cancer; and ThyraMIR, a thyroid cancer test that uses microRNA analysis to detect malignant nodules.
The company has a strong commitment to research and development, with a dedicated team of scientists working to develop new diagnostic tests and improve existing products. In addition to its proprietary diagnostic platforms, Exact Sciences has also formed strategic partnerships with other leading medical technology companies to expand its capabilities in areas such as liquid biopsy and precision medicine.
As of 2021, Exact Sciences has grown to become a multi-billion-dollar company with more than 6,000 employees worldwide. The company has received numerous awards and accolades for its innovative products and commitment to improving healthcare outcomes, and is widely regarded as a leader in the field of molecular diagnostics.
Company Address: 5505 Endeavor Lane Madison 53719 WI
Company Phone Number: 535-8815 Stock Exchange / Ticker: NASDAQ EXAS
| EXAS is expected to report next financial results on February 20, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Hologic Inc
Hologic Inc, a leading Medical Laboratories company, recently released its financial results for the fiscal period ending September 30, 2023. The results indicated a significant decline in income and net profits compared to the previous year. Additionally, the company's operating and net margins contracted, while inventories and accounts receivable witnessed fluctuations. This article aims to outline the facts and interpret the financial performance of Hologic Inc in context.
Financial Results:
1. Income and Earnings Per Share (EPS):
- Hologic Inc's income for the most recent fiscal period fell by -22.69% to $0.36 per share, contrasting with $0.47 per share reported in the previous financial reporting period.
- In the preceding financial reporting period, the company recorded an income per share of $-0.16.
- The decline in EPS is noteworthy, as it has decreased by -64.33% to $1.83 per share from $5.13 per share in the preceding fiscal period.
|
|
Hh And L Acquisition Co
As the earnings cycle resumes for the fiscal period of July-September 2023, a number of entities have disclosed their financial results, including several constituents of the Medical Laboratories sector. One such company is Hh And L Acquisition Co (HHLAU), which recently reported an operating loss of $-4.59154 million for the financial interval ending September 30, 2023.
Analyzing HHLAU's Performance
To accurately assess the fiscal period ending in the third quarter of 2023, it is essential to compare it with its performance in the previous year. In Q3 2022, HHLAU recorded an operating loss of $-1.440693 million. The recent increase in operating loss raises concerns about the firm's ability to sustain and nurture potential revenue streams.
The Stakeholder Analysis
A net loss of $4.769 million in the most recent fiscal period raises several red flags for stakeholders of HHLAU. It suggests potential issues within the company's operations, financial management, or market positioning. Stakeholders, such as investors, lenders, and employees, must closely monitor the company's performance to make informed decisions regarding their involvement with HHLAU.
|
|
Absci Corp
Absci Corp: A Closer Look at the Third Quarter Earnings Report
Absci Corp, a generative AI drug creation company, recently released its earnings report for the third quarter of the 2023 earnings season. The report reveals both positive and negative aspects of the company's financial performance during this period.
To begin with, Absci Corp managed to decrease its loss per share to $-0.24 per share, compared to $-0.30 per share in the previous year. This improvement is a positive sign for shareholders, indicating that the company is taking steps to reduce its losses and move towards profitability.
|
|
Aclarion Inc
The stock market is a dynamic arena where investors scrutinize the financial performance of different companies to make informed investment decisions. Aclarion Inc, a Medical Laboratories company, has recently shared its fiscal results for the most recent reporting period. In this article, we will delve into the interesting facts surrounding the company's performance, analyzing its revenue growth, net shortfall, accounts receivable, and provide insights into its future prospects.
Revenue Growth and Market Position:
During the most recent fiscal period, Aclarion Inc reported reaching a flat valuation of $0.00 per share, which was consistent with the previous year's figure. However, it's worth noting that the company's revenue increased moderately by 4.626% to $0.02 million from the corresponding period a year ago. This positive revenue growth places Aclarion Inc in a favorable position within the Medical Laboratories industry, which witnessed an overall 4.27% top-line growth during the same period. Sequentially, Aclarion Inc's revenue advanced by 11.674% from the preceding financial reporting period, demonstrating its ability to sustain growth and expand its market share.
|
|
Opgen Inc
During the past 5 trading days, Opgen Inc's stock experienced a significant decrease of -16.27%. This dip brings the year-to-date performance to an impressive 184.36%. Currently, Opgen Inc's stock is trading on the NASDAQ at a value that is -39.6% below its 52-week average.
Recent financial reports from Opgen Inc show interesting developments. For the interval between July and September 30, 2023, OPGN's deficit has increased by $-0.46 per share when compared to the same period a year prior. On the other hand, the earnings per share have improved from $-0.93 per share in the preceding quarter. This indicates a mixed performance for the company's financial results.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.57 $ |
| Revenues (TTM) |
13.08 $
|
| Cash Flow (TTM) |
1.95 $ |
| Cash |
3.99 $
|
| Book Value |
16.96 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.57 $
|
| Revenues (TTM) |
13.08 $ |
| Cash Flow (TTM) |
1.95 $ |
| Cash |
3.99 $
|
| Book Value |
16.96 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
